Proton Therapy for Prostate Cancer

Emine GÖKÇEOĞLU¹, Ming Yang^2, , Tae Lee² and Sibel KÜÇÜKOĞLU^3,

¹Muş Alparslan University, Health High School, Department of Child Health and Disease, Nursing, Erzurum/Turkey

²Daliao District Fooyin, Kaohsiung, Taiwan, Republic of China

³Atatürk University, Faculty of Health Science, Department of Child Health and Disease Nursing, Erzurum/Turkey

Cite this paper:
Emine GÖKÇEOĞLU, Ming Yang, Tae Lee and Sibel KÜÇÜKOĞLU. Proton Therapy for Prostate Cancer. Journal of Cancer Research and Treatment. 2014; 2(4):69-70. doi: 10.12691/jcrt-2-4-1

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Wilson R. Radiological use of fast protons. Radiology. 1946; 47: 487-91.
[2]	Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate cancer: current status and controversies. British Journal of Cancer (2013) 108, 1225-1230.
[3]	Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007; 69 (2): 444-53.
[4]	Rana S, Cheng C, Zheng Y, Risalvato D, Cersonsky N, Ramirez E, Zhao L, Larson G, Vargas C. Proton therapy vs. VMAT for prostate cancer: a treatment planning study. International Journal of Particle Therapy 2014; 1 (1): 22-33.
[5]	Zhang X, Dong L, Lee AK, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007; 67 (2): 620-29.
[6]	Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70 (3): 744-51.
[7]	Chera BS, Vargas C, Morris CG, et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J RadiatOncolBiol Phys. 2009; 75 (4): 994-1002.
[8]	Nihei K, Ogino T, Onozawa M, et al. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011; 81 (2):390-96.
[9]	Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu HM, Engelsman M, Merrick S, Cheng CW, Wong JR, Zietman AL. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 1; 80 (3): 928-37.
[10]	Tang S, Both S, Bentefour H, et al. Improvement of prostate treatment by anterior proton fields. Int J Radiat Oncol Biol Phys. 2012; 83 (1):408-18.
[11]	Rana S, Cheng C, Zheng Y, Hsi W, Zeidan O, Schreuder N, Vargas C, Larson G. Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prosthesis, and comparison with volumetric-modulated arc therapy. Journal of Applied Clinical Medical Physics 2014; 15 (3): 4611.
[12]	http://www.pcgresearch.org/Pages/ResearchStudies.aspx
[13]	Tesfamicael BY, Avery S, Gueye P, Lyons D, Mahesh M. Scintillating fiber based in-vivo dose monitoring system to the rectum in proton therapy of prostate cancer: A Geant4 Monte Carlo simulation. Int J Cancer TherOncol 2014; 2 (2): 02024.
[14]	Yeung D, McKenzie C, Indelicato DJ. A dosimetric comparison of intensity-modulated proton therapy optimization techniques for pediatric craniopharyngiomas: a clinical case study. Pediatr Blood Cancer. 2014 Jan; 61 (1): 89-94.